• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患儿长期中心静脉导管中生物膜的形成:替考拉宁与肝素的随机对照开放标签试验。

Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.

机构信息

Department of Paediatrics, Aarhus University Hospital Skejby, Denmark.

出版信息

APMIS. 2012 Oct;120(10):794-801. doi: 10.1111/j.1600-0463.2012.02910.x. Epub 2012 May 15.

DOI:10.1111/j.1600-0463.2012.02910.x
PMID:22958287
Abstract

Taurolidine has demonstrated inhibition of biofilm formation in vitro. The aim of this study was to compare the effect of catheter locking with taurolidine vs heparin in biofilm formation in central venous catheters. Forty-eight children with cancer were randomized to catheter locking by heparin (n = 22) or taurolidine (n = 26), respectively. After removal, catheters were examined by standardized scanning electron microscopy to assess quantitative biofilm formation. Biofilm was present if morphologically typical structures and bacterial cells were identified. Quantitative and semi-quantitative cultures were also performed. Biofilm was identified in 23 of 26 catheters from the taurolidine group and 21 of 22 catheters from the heparin group. A positive culture was made of six of the catheters locked with taurolidine and heparin, respectively (p = 0.78). The rate of catheter-related bloodstream infections (CRBSI) was 0.1 per 1000 catheter-days using taurolidine and 0.9 per 1000 catheter-days using heparin (p = 0.03). This randomized trial confirmed that the use of taurolidine as catheter-lock compared with heparin reduced the rate of CRBSIs; this reduction was not related to a reduction in the intraluminal biofilm formation and the rate of bacterial colonization detected by scanning electron microscopy in the two groups.

摘要

替考拉宁已证明可抑制生物膜的体外形成。本研究旨在比较替考拉宁与肝素对中心静脉导管生物膜形成的导管锁定作用。将 48 例癌症患儿随机分为肝素(n=22)或替考拉宁(n=26)导管锁定组。导管取出后,采用标准化扫描电子显微镜检查评估定量生物膜形成情况。如果形态典型结构和细菌细胞被识别,则存在生物膜。还进行了定量和半定量培养。替考拉宁组 26 个导管中有 23 个存在生物膜,肝素组 22 个导管中有 21 个存在生物膜。替考拉宁和肝素分别有 6 个导管的培养呈阳性(p=0.78)。使用替考拉宁的导管相关血流感染(CRBSI)发生率为每 1000 个导管日 0.1 例,使用肝素的发生率为每 1000 个导管日 0.9 例(p=0.03)。这项随机试验证实,与肝素相比,替考拉宁作为导管封管可降低 CRBSI 的发生率;这种降低与两组扫描电子显微镜检测到的管腔内生物膜形成和细菌定植率降低无关。

相似文献

1
Biofilm formation in long-term central venous catheters in children with cancer: a randomized controlled open-labelled trial of taurolidine versus heparin.癌症患儿长期中心静脉导管中生物膜的形成:替考拉宁与肝素的随机对照开放标签试验。
APMIS. 2012 Oct;120(10):794-801. doi: 10.1111/j.1600-0463.2012.02910.x. Epub 2012 May 15.
2
Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.柠檬酸牛磺菌素与肝素在儿童血液恶性肿瘤患者中作为导管封管液的随机对照试验。
J Hosp Infect. 2012 Apr;80(4):304-9. doi: 10.1016/j.jhin.2012.01.003. Epub 2012 Feb 18.
3
Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin.癌症患儿中心静脉导管和导管锁:替考拉宁与肝素的前瞻性随机试验。
Pediatr Blood Cancer. 2013 Aug;60(8):1292-8. doi: 10.1002/pbc.24482. Epub 2013 Feb 15.
4
Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.使用含枸橼酸-牛磺罗定的封管溶液预防透析导管相关败血症。
Nephrol Dial Transplant. 2004 Jun;19(6):1546-51. doi: 10.1093/ndt/gfh014. Epub 2004 Feb 19.
5
Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.锁定解决方案对隧道式血液透析导管中条件生物膜形成和炎症反应激活的影响。
J Vasc Access. 2021 May;22(3):370-379. doi: 10.1177/1129729820942040. Epub 2020 Jul 21.
6
Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).使用牛磺罗定 - 柠檬酸盐封管溶液预防成年中性粒细胞减少血液学患者中心静脉导管感染:一项随机、双盲、安慰剂对照试验(TAURCAT)
Trials. 2018 May 2;19(1):264. doi: 10.1186/s13063-018-2647-y.
7
Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.经替考拉宁管路封管治疗后,开始 HPN 的儿童中心静脉导管相关血流感染显著减少。
J Pediatr Gastroenterol Nutr. 2012 Oct;55(4):403-7. doi: 10.1097/MPG.0b013e31825bb0ae.
8
A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens From the Catheter Biofilm in Hemodialysis Patients.一种牛磺罗定 - 柠檬酸盐 - 肝素封管溶液可有效清除血液透析患者导管生物膜中的病原体。
Am J Ther. 2016 Mar-Apr;23(2):e363-8. doi: 10.1097/MJT.0b013e31828d4610.
9
Taurolidine and Heparin as Catheter Lock Solution for Central Venous Catheters in Hemodialysis.牛磺酸和肝素作为血液透析中心静脉导管的封管液。
Am J Ther. 2024;31(4):e398-e409. doi: 10.1097/MJT.0000000000001736. Epub 2024 May 7.
10
A vancomycin-heparin lock solution for prevention of nosocomial bloodstream infection in critically ill neonates with peripherally inserted central venous catheters: a prospective, randomized trial.用于预防经外周静脉穿刺中心静脉置管的危重新生儿医院血流感染的万古霉素 - 肝素封管液:一项前瞻性随机试验。
Pediatrics. 2005 Aug;116(2):e198-205. doi: 10.1542/peds.2004-2674. Epub 2005 Jul 1.

引用本文的文献

1
The Antiseptic and Antineoplastic Agent Taurolidine Modulates Key Leukocyte Functions.牛磺罗定作为一种防腐和抗肿瘤药物,调节关键白细胞功能。
In Vivo. 2022 Sep-Oct;36(5):2074-2082. doi: 10.21873/invivo.12933.
2
Exploring the potential of taurolidine in inducing mobilization and detachment of colon cancer cells: a preliminary in-vitro study.探讨牛磺罗定在诱导结肠癌细胞迁移和脱落中的作用:一项初步的体外研究。
BMC Pharmacol Toxicol. 2022 Jun 13;23(1):38. doi: 10.1186/s40360-022-00572-8.
3
Short bowel syndrome in infancy: recent advances and practical management.
婴儿短肠综合征:最新进展与实际管理
Frontline Gastroenterol. 2020 Dec 16;12(7):614-621. doi: 10.1136/flgastro-2020-101457. eCollection 2021.
4
Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer.预防抗生素用于预防与成人和儿童癌症治疗期间长期使用中心静脉导管相关的革兰氏阳性感染。
Cochrane Database Syst Rev. 2021 Oct 7;10(10):CD003295. doi: 10.1002/14651858.CD003295.pub4.
5
Vancomycin-lock therapy for prevention of catheter-related bloodstream infection in very low body weight infants.万古霉素封管疗法预防极低出生体重儿导管相关血流感染。
BMC Pediatr. 2021 Jan 4;21(1):3. doi: 10.1186/s12887-020-02482-2.
6
Use of Catheter Lock Solutions in Patients Receiving Home Parenteral Nutrition: A Systematic Review and Individual-Patient Data Meta-Analysis.接受家庭肠外营养患者中使用导管锁定溶液:系统评价和个体患者数据荟萃分析。
JPEN J Parenter Enteral Nutr. 2020 Sep;44(7):1198-1209. doi: 10.1002/jpen.1761. Epub 2020 Jan 27.
7
Central Venous Access Devices (CVAD) in Pediatric Oncology Patients-A Single-Center Retrospective Study Over More Than 9 Years.儿科肿瘤患者的中心静脉通路装置(CVAD)——一项超过9年的单中心回顾性研究
Front Pediatr. 2019 Jun 25;7:260. doi: 10.3389/fped.2019.00260. eCollection 2019.
8
Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition.随机临床试验:2%牛磺罗定与 0.9%生理盐水在家肠外营养患者中的封管比较。
Aliment Pharmacol Ther. 2018 Aug;48(4):410-422. doi: 10.1111/apt.14904. Epub 2018 Jul 5.
9
Anticoagulation for people with cancer and central venous catheters.癌症患者及中心静脉导管置入者的抗凝治疗
Cochrane Database Syst Rev. 2018 Jun 1;6(6):CD006468. doi: 10.1002/14651858.CD006468.pub6.
10
Comparative Efficacies of Antimicrobial Catheter Lock Solutions for Fungal Biofilm Eradication in an in Vitro Model of Catheter-Related Fungemia.抗菌导管封管溶液在导管相关真菌血症体外模型中根除真菌生物膜的比较疗效
J Fungi (Basel). 2017 Feb 10;3(1):7. doi: 10.3390/jof3010007.